Catriona Yale

2021

In 2021, Catriona Yale earned a total compensation of $1.8M as Chief Development Officer at Akero Therapeutics.

Compensation breakdown

Non-Equity Incentive Plan$160,684
Option Awards$1,190,645
Salary$401,709
Total$1,753,038

Yale received $1.2M in option awards, accounting for 68% of the total pay in 2021.

Yale also received $160.7K in non-equity incentive plan and $401.7K in salary.

Rankings

In 2021, Catriona Yale's compensation ranked 6,575th out of 12,406 executives tracked by ExecPay. In other words, Yale earned more than 47.0% of executives.

ClassificationRankingPercentile
All
6,575
out of 12,406
47th
Division
Manufacturing
2,833
out of 5,492
48th
Major group
Chemicals And Allied Products
1,247
out of 2,368
47th
Industry group
Drugs
1,112
out of 2,089
47th
Industry
Pharmaceutical Preparations
805
out of 1,536
48th
Source: SEC filing on April 28, 2023.

Yale's colleagues

We found four more compensation records of executives who worked with Catriona Yale at Akero Therapeutics in 2021.

2021

Andrew Cheng

Akero Therapeutics

Chief Executive Officer

2021

Jonathan Young

Akero Therapeutics

Chief Operating Officer

2021

Timothy DPhil

Akero Therapeutics

Chief Scientific Officer

2021

William White

Akero Therapeutics

Chief Financial Officer

News

In-depth

You may also like